GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hubei Guangji Pharmaceutical Co 000952.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

5.57

-1.76%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hubei Guangji Pharmaceutical Co

Its shares trade on Shenzhen under the ticker 000952.SZ. It has been listed since 12 November 1999. In the fiscal year to 31 December 2025, it reported revenue of CN¥624.0m and a net loss of CN¥404.5m. At that date it held total assets of CN¥2.31bn and shareholders' equity of CN¥653.8m.

Hubei Guangji Pharmaceutical Co., Ltd. engages in the production and operation of pharmaceutical raw materials, pharmaceutical preparations, and feed additives. The company is headquartered in Huanggang, Hubei. The firm mainly provides bulk drugs and pharmaceutical preparations. Its bulk drugs include pharmaceutical grade products, food grade products, 98% feed grade products, 80% feed grade riboflavin and riboflavin sodium phosphate. Its preparation products include oral solid preparations and infusion products. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
12 Nov 1999
Employees
1,256

Leadership

Pay as last reported

  • Mr. Ligang HuChairman of the Board, since 2024
  • Mr. Yi XiongChief Financial Officer
  • Mr. Cheng GongGeneral Manager, Director, since 2024
  • Mr. Lin YangGeneral Manager, since 2017
  • Mr. Zhi FangDeputy General Manager, Director, Chief Engineer, since 2024
  • Mr. Shaozhi GuoDeputy General Manager, Director, since 2005CN¥418,900
  • Zhanghua ChengDeputy General ManagerCN¥60,000
  • Mr. Mingfeng HuDeputy General Manager, since 2018
  • Mr. Zhengdong LuDeputy General ManagerCN¥130,600
  • Mr. Zhongyi RuanDeputy General Manager, since 2006CN¥400,500
  • Xin WangDeputy General Manager, since 2006CN¥551,500
  • Mr. Yanhua ZhaoDeputy General Manager

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company employs 1256 full-time staff members in Huanggang.
  • Production includes pharmaceutical grade bulk drugs and feed additives.
  • Oral solid preparations and infusion products are key offerings.

Weaknesses

  • Domestic market distribution limits international revenue potential significantly.
  • Reliance on bulk drugs reduces product diversification breadth.
  • Hubei location may increase logistical costs for exports.

Opportunities

  • Overseas markets offer significant growth for feed additives.
  • Food grade products can expand into new segments.
  • Riboflavin sodium phosphate has potential in specialized therapies.

Threats

  • Competition in the pharmaceutical raw materials sector is intense.
  • Regulatory changes in China affect production standards heavily.
  • Fluctuating demand for feed additives impacts revenue stability.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.